An observational, practice based, open label, prospective, non-comparative, multicenter, post marketing surveillance to assess safety and tolerability of Liposomal Amphotericin B (Phosome) in patients with Invasive Fungal Infection who are refractory to or intolerant of conventional Amphotericin B therapy.

Cipla Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年3月4日

试验速览

暂无简介。

•1.Written signed and dated informed consent (patient or LAR).
•2.Either gender with age =18 years.
•3.Patients with Invasive Fungal Infection (IFI) who are refractory to or intolerant of conventional Amphotericin B therapy, as per physician’s discretion.
•4.Culture proven Aspergillus, Candida, Cryptococcus Invasive Fungal Infection (IFI).
•5.Patients who are either treatment naïve to Liposomal Amphotericin B or have started Liposomal Amphotericin B treatment within 5 days for the current Invasive Fungal Infection episode.

•1.Known hypersensitivity to Liposomal Amphotericin B or any of its components
•2.Pregnant or nursing females
•3.Any other condition in the opinion of the investigator would affect the safety of the patient if Liposomal Amphotericin B is administered.

发起方